arrow
Y

Yair Lotan

university of texas southwestern medical center
H指数:113
被引数:6.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective multicenter validation of a Urine-Based multiplex assay for risk stratification of patients presenting with gross hematuria

基于尿液的多重检测方法在评估肉眼血尿患者风险分层中的多中心前瞻性验证

2026-08-170
OAAI
Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

将临床可操作生物标志物整合到膀胱癌护理中——国际膀胱癌小组的建议

2026-08-050
PRE
Active surveillance in low-grade NMIBC — results of an international two-round modified Delphi consensus

低级别非肌层浸润性膀胱癌中的主动监测——国际两轮改良德尔菲共识的结果

2026-04-010
PRE
Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates

Ga68-PSMA-PET阳性转移性激素敏感性前列腺癌患者中,有无常规影像学检查对照的真实世界治疗结局

2025-12-010
PRE
Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomy

组织学分级是否是浸润性尿路上皮膀胱癌的有用参数?来自一项关于不同分级系统对根治性膀胱切除术术后无病生存期影响的多中心研究的结果

2025-11-200
OAAI
Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group

非肌层浸润性膀胱癌的中危风险:国际膀胱癌小组关于定义、风险分层、管理策略和临床试验设计的建议

2025-10-100
PRE
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder

膀胱原位癌对卡介苗无反应的治疗方案的成本效益分析

2025-10-040
PRE
Impact of timing of computed tomography staging and patient factors on the detection of ‘true’ cN+ bladder cancer

计算机断层扫描分期时间及患者因素对检测“真”cN+膀胱癌的影响

2025-07-090
OAAI
Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes

计算组织学人工智能(CHAI)在多中心队列中增强了高级别Ta非肌肉浸润性膀胱癌的风险分层:与当前欧洲泌尿外科学会和美國泌尿外科学会分层方案的比较

2025-06-120
PRE
Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer

人工智能驱动的预测性生物标志物的存在与高危非肌层浸润性膀胱癌患者对膀胱内卡介苗治疗的反应不佳相关,但与对膀胱内序贯吉西他滨/多西他赛治疗的反应无关。

2025-04-250
OAAI